|Issuer:||LOGICBIO THERAPEUTICS, INC. (LOGC)|
|Original Submission Date:|
C/O LOGICBIO THERAPEUTICS, INC.
65 HAYDEN AVE, FLOOR 2 LEXINGTON, MA 02421
|Title of Security||Transaction Date||2a. Deemed Execution Date||Transaction Code||Shares||Acquired or Disposed||Price per share||5. Amount of Securities Beneficially Owned Following Reported Transaction||6. Ownership Form Direct or Indirect||Nature of Indirect Ownership|
|Title of Derivative Security||Conversion or Exercise Price of Derivative Security||Transaction Date||Deemed Execution Date||Transaction Code||Number of Derivative Securities Acquired (A) or Disposed of (D)||Date Exercisable||Expiration Date||Title and Amount of Securities Underlying Derivative Security||Price of Derivative Security||Number of derivative Securities Beneficially Owned Following Reported Transaction(s)||Ownership Form: Direct (D) or Indirect (I)||Nature of Indirect Beneficial Ownership|
|STOCK OPTION (RIGHT TO BUY)||4.59||2021-06-11||deemed execution date||A||12,500 (a)||2031-06-11||common stock 12,500||$4.59||12,500||direct|
|f1||the options were granted by the issuer pursuant to its 2018 equity incentive plan as provided under the company's compensation policy for non-employee directors. all of the options will vest and become exercisable on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the company's 2022 annual meeting of stockholders, subject to the reporting person's continuous service with the issuer through the vesting date.|